I approach induction therapy for locally advanced disease in a similar way to adjuvant chemotherapy, and use many of the same regimens. For adenocarcinoma, I prefer a pemetrexed-based regimen–cisplatin or carboplatin depending on age and co-morbidities. I avoid bevacizumab in these patients if...